Abterra Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Abterra Biosciences is a private, revenue-generating service provider in the antibody discovery and sequencing space. The company offers a suite of technology platforms (REPTOR, ALICANTO, VALENS, GRIFFIN) that enable partners to identify and characterize therapeutic antibodies from various sources, including hybridomas, B cells, serum, and polyclonal mixtures. With roots as a UCSD spin-out (originally Digital Proteomics LLC), Abterra combines deep bioinformatics expertise with wet-lab services to accelerate antibody therapeutic development for its clients, which include biotech companies and academic institutions.

Antibodies

Technology Platform

Integrated platform combining next-generation sequencing (NGS), mass spectrometry, and proprietary machine learning algorithms for comprehensive antibody discovery, sequencing, and characterization from various sources (B cells, serum, hybridomas, polyclonal mixtures).

Opportunities

The growing therapeutic antibody market and the industry's need for faster, more comprehensive discovery tools create significant demand for Abterra's services.

The recent launch of GRIFFIN for polyclonal antibody sequencing addresses a specific, high-value niche to ensure product consistency.

The company's species-agnostic approach and direct-from-protein sequencing capabilities provide a competitive edge in servicing a diverse client base.

Risk Factors

Abterra operates in a highly competitive contract research and sequencing services market, where technological differentiation is key.

Its revenue is directly tied to biopharma R&D spending, making it vulnerable to sector funding downturns.

As a service-only business, it lacks the asset upside of a therapeutic developer and faces linear growth constraints.

Competitive Landscape

Abterra competes with a broad range of players, including large CROs (e.g., Charles River, Lonza) offering antibody discovery services, specialized genomics/proteomics companies (e.g., Pacific Biosciences, 10x Genomics for NGS; Seer, Nautilus for proteomics), and other niche antibody sequencing firms. Its differentiation lies in the integrated use of mass spectrometry and NGS, its proprietary bioinformatics, and its unique direct-from-protein sequencing capabilities.

More companies in Biologics / Biosimilars →More companies in United States →